Benefits PT-141 studied for libido enhancement and central melanocortin receptor activation MT-2 explored for its role in tanning, photoprotection, and sexual arousal effects Oxytocin linked to bonding, attraction, and intimacy Synergistic blend combines melanocortin and oxytocin pathways for enhanced sexual health research Fast-acting nasal delivery provides rapid uptake and central action Localized Effects with Nasal Spray Rapid uptake through the nasal mucosa Direct influence on central melanocortin and oxytocin signaling pathways Formulated with a specialized isotonic nasal vehicle to minimize irritation and dryness What Researchers Use It For Studies on sexual arousal and libido involving melanocortin receptor pathways Research on photoprotection and pigmentation with MT-2 Explorations of bonding and social effects through oxytocin pathways Investigation of combined peptide blends for intimacy and attraction behaviors Identity & Specs Blend Content: PT-141 (10 mg), MT-2 (10 mg), Oxytocin (1 mg) Total Content: 21 mg peptides per vial Form: Sterile nasal spray solution Net per vial: 10 mL (~100 sprays) Per Spray: ~210 mcg total blend Purity: 99% (HPLC) Identity: MS-verified (per COA) Storage: Refrigerate 28 C, protect from light Selected Research PT-141 clinical trial in sexual dysfunction: MT-2 melanocortin receptor and tanning effects: Oxytocin and bonding studies: Melanocortin pathways in arousal: Disclaimer This product is intended for laboratory research use only
Fewer cardiac events In a trial of 17,604 adults with heart disease, semaglutide cut major cardiac events heart attack, stroke, cardiac death by 20% (New England Journal of Medicine, 2023)
I have used several other companies for my IV therapy in the past but never have I had such a great experience- and on a boat with water time for the same price
A conventional glutathione tablet raises blood levels only slightly
The company has made headlines for waging litigation against clinics, med spas, and pharmacies over the past year, with many of those cases settling out of court and the defendants agreeing to permanently refrain from using any Novo Nordisk trademarks or logos and from engaging in any misleading advertising with regard to compounded semaglutide products, among other things
